(Q37462525)

20 August 2017

Benefits and risks of combination therapy for hepatitis B. (English)

1 reference

20 August 2017

Norah A Terrault

1

1 reference

PubMed ID

19399796

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

49

1 reference

20 August 2017

5 Suppl

1 reference

20 August 2017

S122-8

1 reference

Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis

20 August 2017

1 reference

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

21 January 2018

1 reference

Virology of hepatitis B and C viruses and antiviral targets

21 January 2018

1 reference

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

7 January 2021

HBV drug resistance: mechanisms, detection and interpretation

1 reference

7 January 2021

Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.

1 reference

7 January 2021

1 reference

7 January 2021

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

7 January 2021

Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective

1 reference

7 January 2021

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

1 reference

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

7 January 2021

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

7 January 2021

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

1 reference

7 January 2021

Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.

1 reference

7 January 2021

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

1 reference

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

7 January 2021

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

1 reference

7 January 2021

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

7 January 2021

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

7 January 2021

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22921

1 reference

20 August 2017

1 reference

PubMed ID

19399796